No Data
No Data
Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Oppenheimer Sticks to Its Buy Rating for Clearside Biomedical (CLSD)
Express News | Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
JMP Securities Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Clearside Biomedical's Promising CLS-AX Treatment in the ODYSSEY Trial: A Buy Rating Based on Safety and Potential Market Impact
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $4
No Data